Trial · NCT07882485
Effects of Web-Based Ovarian Cancer Awareness Education on Women's Health Beliefs and Risk-Reducing Behaviors
NCT07882485, Not applicable, Not yet recruiting, Ege University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Web-Based Ovarian Cancer Awareness Education on Women's Health Beliefs and Risk-Reducing Behaviors. Trials, record NCT07882485. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882485
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Web-Based Ovarian Cancer Awareness Education on Women's Health Beliefs and Risk-Reducing Behaviors
- NCT number
- NCT07882485
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 82 participants, estimated
- Lead sponsor
- Ege University
- Conditions
- Ovarian Cancer
- Interventions
- Web-Based Ovarian Cancer Awareness Education, General Reproductive Health Information
- First posted
- 2026-10-20
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Ovarian Cancer Symptom Recall Score | Baseline and three months after completion of the four-week education period (approximately four months after baseline). | Change from baseline in the symptom recall score of the Turkish version of the Ovarian Cancer Awareness Scale. Participants will list ovarian cancer symptoms in an open-ended question. Each correctly recalled symptom will receive 1 point, with scores ranging from 0 to 10. Higher scores indicate greater awareness of ovarian cancer symptoms. Changes will be compared between the intervention and control groups. |
| Primary | Change in Ovarian Cancer Symptom Recognition Score | Baseline and three months after completion of the four-week education period (approximately four months after baseline). | Change from baseline in the symptom recognition score of the Turkish version of the Ovarian Cancer Awareness Scale. Participants will identify whether each of 10 listed symptoms could be a symptom of ovarian cancer, using "yes," "no," or "don't know" responses. Each "yes" response will receive 1 point; "no" and "don't know" responses will receive 0 points. Scores range from 0 to 10, with higher scores indicating greater symptom recognition. Changes will be compared between the intervention and control groups. |
| Primary | Change in Ovarian Cancer Risk Factor Recall Score | Baseline and three months after completion of the four-week education period (approximately four months after baseline). | Change from baseline in the risk factor recall score of the Turkish version of the Ovarian Cancer Awareness Scale. Participants will list ovarian cancer risk factors in an open-ended question. Each correctly recalled risk factor will receive 1 point, with scores ranging from 0 to 12. Higher scores indicate greater awareness of ovarian cancer risk factors. Changes will be compared between the intervention and control groups. |
| Primary | Change in Ovarian Cancer Risk Factor Awareness Score | Baseline and three months after completion of the four-week education period (approximately four months after baseline). | Change from baseline in the risk factor awareness score of the Turkish version of the Ovarian Cancer Awareness Scale. This section includes 12 items rated on a five-point Likert scale, from 1 (strongly disagree) to 5 (strongly agree). Scores range from 12 to 60. Higher scores indicate greater awareness of ovarian cancer risk factors. Changes will be compared between the intervention and control groups. |
| Secondary | Change in Perceived Severity Subscale Score of the Cancer Screening Perception Scale | Baseline and three months after completion of the four-week education period (approximately four months after baseline). | Change from baseline in the perceived severity subscale score of the Turkish version of the Cancer Screening Perception Scale. This subscale consists of four items rated on a six-point Likert scale. Scores range from 4 to 24. According to the scoring description, higher scores indicate lower perceived severity. Changes will be compared between the intervention and control groups. |
| Secondary | Change in Perceived Susceptibility Subscale Score of the Cancer Screening Perception Scale | Baseline and three months after completion of the four-week education period (approximately four months after baseline). | Change from baseline in the perceived susceptibility subscale score of the Turkish version of the Cancer Screening Perception Scale. This subscale consists of five items rated on a six-point Likert scale. Scores range from 5 to 30. Higher scores indicate lower perceived susceptibility. Changes will be compared between the intervention and control groups. |
| Secondary | Change in Perceived Benefits Subscale Score of the Cancer Screening Perception Scale | Baseline and three months after completion of the four-week education period (approximately four months after baseline). | Change from baseline in the perceived benefits subscale score of the Turkish version of the Cancer Screening Perception Scale. This subscale consists of six items rated on a six-point Likert scale. Scores range from 6 to 36. Higher scores indicate greater perceived benefits of cancer screening tests. Changes will be compared between the intervention and control groups. |
| Secondary | Change in Perceived Barriers Subscale Score of the Cancer Screening Perception Scale | Baseline and three months after completion of the four-week education period (approximately four months after baseline). | Change from baseline in the perceived barriers subscale score of the Turkish version of the Cancer Screening Perception Scale. This subscale consists of five items rated on a six-point Likert scale. Scores range from 5 to 30. Higher scores indicate greater perceived barriers to cancer screening. Changes will be compared between the intervention and control groups. |
| Secondary | Change in Cues to Action Subscale Score of the Cancer Screening Perception Scale | Baseline and three months after completion of the four-week education period (approximately four months after baseline). | Change from baseline in the cues to action subscale score of the Turkish version of the Cancer Screening Perception Scale. This subscale consists of six items rated on a six-point Likert scale. Scores range from 6 to 36. According to the scoring description, higher scores indicate a greater number of self-reported symptoms that may prompt action. Changes will be compared between the intervention and control groups. |
| Secondary | Change in Item-Level Responses on the Ovarian Cancer Risk-Reducing Behavior Awareness Form | Baseline and three months after completion of the four-week education period (approximately four months after baseline). | A researcher-developed 15-item form will assess self-reported lifestyle behaviors, symptom-related healthcare seeking, and intentions regarding physician-recommended diagnostic or preventive procedures. Each item has five response categories: never, rarely, sometimes, often, and always. For each item, the percentage of participants selecting each response category will be calculated at baseline and follow-up, and changes will be compared between groups. Items will be analyzed separately; no total score will be calculated. More frequent genital talc use will not be interpreted as a favorable change. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882485
GET https://conductscience.org/api/trials/v1/NCT07882485/registered